Skip to main content
. 2019 May 16;10(4):1297–1317. doi: 10.1007/s13300-019-0630-6

Table 3.

Sensitivity analyses results for semaglutide 1 mg versus dulaglutide 1.5 mg based on SUSTAIN 7

Analysis Discounted quality-adjusted life expectancy (QALYs) Discounted direct costs (DKK) ICER (DKK per QALY gained)
Semaglutide 1 mg Dulaglutide 1.5 mg Difference Semaglutide 1 mg Dulaglutide 1.5 mg Difference
Base case 9.41 9.08 + 0.34 402,073 415,489 − 13,416 Semaglutide dominant
20-year time horizon 8.17 7.88 + 0.28 295,697 306,919 − 11,222 Semaglutide dominant
10-year time horizon 5.48 5.28 + 0.20 152,959 167,743 − 14,785 Semaglutide dominant
Statistically significant differences only 9.40 9.08 + 0.32 403,334 415,489 − 12,156 Semaglutide dominant
First treatment intensification at HbA1c ≥ 7.0% and second intensification at HbA1c ≥ 7.5% 9.16 8.88 + 0.28 427,307 438,257 − 10,950 Semaglutide dominant
First treatment intensification at HbA1c ≥ 8.0% and second intensification at HbA1c ≥ 8.5% 9.59 9.24 + 0.34 383,083 390,248 − 7165 Semaglutide dominant
Treatment intensification at 3 years  9.65 9.54 + 0.11 386,173 382,932 + 3242 30,408
Treatment intensification at 5 years 9.72 9.60 + 0.12 375,320 371,568 + 3753 31,721
GLP-1 receptor agonist treatment continued for patient lifetimes 9.45 9.08 + 0.37 476,223 502,717 − 26,494 Semaglutide dominant
Cost of complications + 25% 9.41 9.08 + 0.34 436,659 454,138 − 17,479 Semaglutide dominant
Cost of complications − 25% 9.41 9.08 + 0.34 367,496 376,849 − 9353 Semaglutide dominant
All costs + 25% 9.41 9.08 + 0.34 499,312 516,115 − 16,803 Semaglutide dominant
All costs − 25% 9.41 9.08 + 0.34 304,842 314,872 − 10,030 Semaglutide dominant
Lee et al. BMI disutility applied 8.96 8.57 + 0.40 402,073 415,489 − 13,416 Semaglutide dominant
Evans et al. hypoglycemia disutilities applied 9.30 8.94 + 0.37 402,073 415,489 − 13,416 Semaglutide dominant
Currie et al. hypoglycemia disutilities applied 9.49 9.17 + 0.32 402,073 415,489 − 13,416 Semaglutide dominant

BMI body mass index, DKK 2017 Danish kroner, HbA1c glycated hemoglobin, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year